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Abstract: Introduction: In Germany, stroke is the third leading cause of death, with more than
60,000 fatalities out of approximately 260,000 cases (first-ever and recurrent strokes) each year.
So far, there are only a few long-term studies investigating determinants of the natural course of the
disease, especially in the era of mechanical thrombectomy. Materials and Methods: The prospective
single-center stroke cohort Augsburg (SCHANA) study will include about 1000 patients treated for
stroke in the University Hospital of Augsburg. Patients aged 18 years or older with a confirmed
diagnosis of ischemic or hemorrhagic stroke are included in the study. Information on demographic
characteristics, onset of symptoms, etiologic factors, comorbidities, quality of life, invasive and
non-invasive treatment, complications, and laboratory parameters are collected during a personal
interview conducted during the patients’ hospital stay and via a medical chart review. About 30 mL
of blood is collected from each patient, and after processing and aliquoting, all blood specimens are
frozen at −80◦ C. The study participants will be followed-up via postal questionnaires at three and
12 months after discharge from the hospital. Furthermore, mortality follow-ups will be conducted.
Cox-regression analysis will be used to estimate relative risks. Conclusion: The SCHANA study
will generate comprehensive data on the long-term course of the disease. In addition to the main
outcomes, recurrent events and survival, patient-oriented outcomes such as health-related quality of
life and depression are the focus of the study.
Keywords: stroke; health care; mortality; complications; recurrence; patient cohort
1. Introduction
According to the World Health Organization (WHO), approximately 15 million people suffer
a stroke every year. A high proportion of the cases are fatal, and one-third of stroke patients are
affected by a serious, permanent disability [1]. In Germany, stroke is the third-leading cause of
death, with more than 60,000 fatalities out of approximately 260,000 cases (first-ever and recurrent
Medicina 2020, 56, 280; doi:10.3390/medicina56060280 www.mdpi.com/journal/medicina
Medicina 2020, 56, 280 2 of 9
strokes) each year [2]. Nearly three-quarters of all strokes occur in people over the age of 65, with the
chances of complete recovery or good functional outcome diminishing with increasing age [3]. A high
number of stroke survivors suffer post-stroke depression, which is characterized by lethargy, irritability,
sleep disturbances, lowered self-esteem, and withdrawal [4]. Up to 10% of people develop seizures
following a stroke; the severity of the stroke increases the likelihood of a seizure [5]. The health-related
quality of life in stroke survivors shows large variability but is lower than that of the general
population [6].
To improve the clinical outcome and recovery of acute ischemic stroke patients, the primary
therapeutic goal is the timely restoration of blood flow to salvageable ischemic brain tissue that is
not already infarcted [7]. Reperfusion therapy using thrombolysis and endovascular interventions
such as mechanical thrombectomy (MT) are the only approved treatments for acute ischemic stroke.
If possible, both methods are applied in an overlapping manner (“bridging” therapy), starting with
systemic thrombolysis and followed by MT. Still, there are no randomized controlled trials that support
additional benefits of tissue plasminogen activator (tPA) application with MT. The current study can
help to examine this in more detail in terms of long-term processes and may contribute to exploring
bridging therapy in addition to advanced imaging-based approaches to select appropriate patients.
Both thrombolysis and mechanical thrombectomy result in an overall benefit regarding living
without disability, but they do not improve survival [8,9]. A portion of patients develop complications
after thrombolysis or thrombectomy [10,11], and the neurological recovery is dependent on the patient’s
baseline functional status, as well as the status of the brain tissue, as assessed by brain imaging. Thus far,
it is not entirely clear which patients are more likely to suffer a complication and which are not. Studies
conducted to answer the question of long-term outcome depending on bridging therapy or MT alone
were either relatively small, and retrospective [12], or the follow-up period was relatively short (max.
of 3 months) with the outcome measures focusing on the modified Rankin Scale alone [13]. The stroke
cohort Augsburg (SCHANA) study will help to identify patient groups that are more likely to be
affected by post-therapeutic complications.
The clinical distinction between ischemic (IS) (thrombotic or embolic) and hemorrhagic strokes
(HS) is of great importance because the management of the various types is very different [3]. Patients
with HS require supportive care and have to be monitored for blood pressure control, changes in
the level of consciousness, and their blood sugar, and oxygenation must be kept at optimum levels.
The prognosis of HS, in general, is worse than for patients with ischemic strokes, but still relatively little
is known about the reasons for differences in the acute phase versus long-term outcomes, especially
concerning the quality of life in both patient groups in correlation with their functional outcomes.
Big registry data are available with the focus on risk factors and outcomes comparing IS and HS,
revealing many similarities (age, sex, and hypertension) but also differences in, e.g., smoking and
alcohol consumption favoring HS [14]. This highlights the importance of analyzing the risk factors
of both IS and HS. However, even large registries focus only on “functional” outcome variables and
mortality and omit health-related quality of life, fatigue or depression, and healthcare utilization.
Furthermore, studies are increasingly focusing on the identification of biomarkers associated with risk
factors and pathogenesis of stroke to make the prevention, diagnosis, and management of stroke more
effective [15,16].
The SCHANA study will provide insight into the risk factors, diagnostic procedures, treatment
options, and the long-term disease course of a stroke. Furthermore, new knowledge regarding the
development, treatment, and prognosis of the disease will be generated by using the information on
genetics and –omics data gained from blood samples. In addition, subgroup differences regarding
treatment effects and patient outcomes such as long-term survival and recurrent events will be assessed.
Patient-oriented outcomes such as quality of life, the burden of depressive disorders, and the extent
of disability in patients with stroke will be investigated. Patient subgroups who would benefit from
certain (novel) therapies will be identified, and knowledge about the safety and harm associated with
the use of drugs will be generated. Specifically, the study will address the following aims:
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1.1. Primary Outcome
To estimate the impact of thrombolysis, mechanical thrombectomy and drug treatment,
comorbidity, treatment-related complications on stroke-related long-term survival, and to examine the
frequency and time point of recurrent events; to examine interaction effects between thrombolysis,
mechanical thrombectomy and drug treatment on the outcome.
1.2. Secondary Outcomes
1. To identify factors which are associated with the natural course of the disease.
2. To identify subgroups of stroke patients (by clinical, physiologic, or psychologic features) and to
assess optimal in-hospital and outpatient treatment for these subgroups.
3. To explore the requirements of bridging therapy (thrombolysis and mechanical thrombectomy).
4. To evaluate the long-term health-related quality of life and the presence of emotional problems,
anxiety and/or depression in stroke patients.
5. To measure and monitor the safety and harm associated with the use of thrombolysis, mechanical
thrombectomy, and drug treatments in hospital and after discharge.
6. To investigate the role of blood biomarkers (e.g., inflammatory parameters, adipokines) and
of “omics” information (genome, metabolome, and proteome data) in disease development,
progression, and outcomes.
7. To determine the health care utilization of patients with stroke, and to determine differences in
health care utilization according to age, gender, socio-economic status, and place of residence
(urban vs. rural).
2. Methods and Analysis
The study includes all consecutive adult patients (18 years and older) with incident as well as
recurrent ischemic and hemorrhagic stroke who are admitted to the University Hospital of Augsburg.
After finishing the pilot study (July/August 2018), the main study began on 1 September, 2018, and is
expected to end on 31 December, 2020 (recruitment phase and follow-up).
Participation in the study is voluntary, and a written, informed consent form has to be signed by
patients who are willing to take part in the study. If a patient suffers from dementia or another disease
with major restrictions, written informed consent is obtained by the responsible legal caregivers, and in
this case, a proxy interview is conducted. An extra study information and consent form is provided for
the legal caregivers. Patients with language difficulties are asked whether a relative is available for
translating the consent form and answering the questions. If this is not possible, patients who are not
able to understand the study information and consent form due to language difficulties, are excluded
from the study. No further exclusion criteria are set. Patients with post-stroke cognitive impairment
(defined by a mini-mental state examination score lower than 27) [17] are included in the study, but will
be excluded from certain data analyses, which are exclusively based on questionnaire data provided
by the patient.
This is also the case for the follow-up questionnaires. For patients with major restrictions,
the responsible legal caregiver will receive the follow-up questionnaires to help the patient with filling
in the questions or to answer the questions as a proxy.
At the University Hospital of Augsburg, a high number of stroke patients are treated-yearly about
1500 cases. Based on the experience in previous, comparable studies, it is expected that about 70
percent of these patients will participate. Data collection procedures are performed in accordance with
the Declaration of Helsinki.
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2.1. Data Collection at Baseline Hospital Stay
2.1.1. Patient Interview and Chart Review
Trained study nurses prospectively record all stroke cases. Once the patients are on the general
ward, they are informed about the study by a study nurse, who also delivers the study documents.
Patients receive comprehensive and understandable information on the processes and consequences of
participation in the study.
After the patients have signed the consent form, they are interviewed by a study nurse. In the
interview, demographic information, symptoms upon presentation, diagnosis, predisposing and
life-style factors, and co-morbidities (e.g., carcinoma, cardiac comorbidity, diabetes mellitus) are
assessed. Clinical data on comorbidities, risk factors, medication prescribed prior to the hospital
stay and at hospital discharge, diagnostic procedures, clinical characteristics, disabilities, laboratory
parameters, and treatment regimens during the hospital stay are assessed by chart review (Table 1).
2.1.2. Collection of Biomaterial
During the hospital stay, about 30 mL of blood is collected from each patient. The blood samples
are processed and aliquoted into sample tubes according to a standardized procedure. The aliquots
are subsequently frozen at −80 ◦C and stored. It is planned to measure pro- and anti-inflammatory
cytokines (e.g., interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, IL-4, IL-10), adipokines (e.g.,
adiponectin, chemerin), neuroimmunokines (e.g., brain-derived growth factor, neurotrophins) and
metabolomics in blood samples
Table 1. Data collected at baseline and during the follow-up.
Patient-Related Characteristics Baseline Examination Follow-Up after 3 Months Follow-Up after 12 Months
Age X
Sex X




Occupation X X X
Smoking X X X
Alcohol consumption X x x
Physical activity
Female health (pregnancy,
childbirth) X x x
Pre-existing diseases X X X
Prior treatments X
Family history of stroke X
Start of stroke symptoms X
(Prior) medication X X X
Vital signs at hospital admission X
Treatment-related variables X







Treatment (e.g., thrombolysis) x
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Table 1. Cont.
Patient-Related Characteristics Baseline Examination Follow-Up after 3 Months Follow-Up after 12 Months
Laboratory values X
General parameters
Date and time of hospital admission X
Date of hospital discharge X
Treatment at ICU and/or stroke unit
Outcome parameters
Health related quality of life X X
Disabilities
Mental health X X
Fatigue
Health care utilization X X
Medication X
Recurrent event X X
Bleeding complications X X
Headache
Vertigo
Dietary intake X X X
2.2. Follow-Up of the Stroke Patients
Morbidity Follow-Up and Update of Treatment, Lifestyle and Health Factors
Three and 12 months after hospital discharge, all study participants will receive postal
questionnaires or telephone interviews. The postal questionnaires will include questions on disease
symptoms, complications, disabilities and comorbidities; behavioral and clinical risk factors (smoking,
alcohol consumption, body weight, height); physical activity (German-PAQ-50+) [18]; health-related
quality of life (Stroke Impact Scale) [19–21] and EQ-5D [22,23]; fatigue and headache (Rostock Headache
Questionnaire) [24]; vertigo and depression (PHQ-9) [25,26]; recurrent events, bleeding outcomes,
and healthcare utilization (readmissions, visits to physicians, clinics, and emergency departments);
and data on current medication. An overview of the data collected at baseline and follow-up is given
in Table 1, and a study flow-chart with enrollment and follow-up is depicted in Figure 1.
2.3. Mortality Follow-Up
Information on deaths occurring in the study sample during follow-up will be collected by
conducting regular mortality follow-ups. The death certificates will be provided by the local health
authorities, and the causes of death will be determined according to the International Classification of
Diseases (ICD)-10 (WHO).
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3. Statistical Analysis
Baseline characteristics will be presented as mean ± standard deviation (SD) or as a median and
interquartile range for continuous variables; categorical variables will be given as percentages. Patient
groups will be compared by Chi-squared test or Fisher’s exact test in case of categorical variables and
by t-test for in case of continuous variables.
Differences between three or more patient subgroups will be conducted through log-linear models
and analysis of variance, and if there are differences, they will be identified using post-hoc-tests.
Cox-Regressions will be carried out for the identification of risk factors and determinants which
are rel t d to t e bina y study outcom . Confounder-adjusted models will be calculated to estimate
relative risks. If a and sex are effect modifi rs will be ex mined. Linear regr ssions will b applied in
c se of continuous outcomes if the model a s mption are fulfilled.
An alpha level of 0.05 will be considered significant within the multivariable analyses. In case of
multiple testing, the significance level alph will be corrected. The statistical analysis will be carried
out using SAS software, SAS Institute, Cary, NC, USA and R project version 3.5.3, Vienna, Austria.
4. Sample Size Estimation
At the University Hospital of Augsburg yearly, about 1500 patients with acute stroke are treated.
Expecting a study participation of about 70% it can be assumed, that altogether about 900 to 1000 patients
will be recruited within one year. Based on a previous meta-analysis [27], a cumulative risk of stroke
recurrence of 11% within one year can be expected. With an estimated hazard ratio (HR) of 1.7 for the
covariate of interest, a variance of 0.36 and a rho2 = 0.3, at least 997 patients have to be included to find
significant differences with a statistical power of 80% (significance level 5%).
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5. Ethics and Dissemination
The study protocol was approved by the Ethics Committee of the Ludwig-Maximilians-Universität
München (date of approval: 29.08.2018, Reference number: 18-196). The study is performed according
to the Declaration of Helsinki. Written informed consent is obtained from each study participant.
Patients who do not consent or are unable to consent are not be included, except for those for which
we obtain consent by the legal caregivers.
6. Discussion
In this manuscript, the protocol for a long-term prospective observational cohort study, including
patients with acute stroke treated in a hospital, is presented. In this study, the factors associated with the
long-term course of this patient group will be investigated. At baseline, data on comorbidities, lifestyle
factors, invasive and non-invasive diagnostic and treatment procedures as well as complications during
a hospital stay is collected by a personal interview and a chart review. Three and twelve months
after hospital discharge, follow-up data will be gathered via postal questionnaires. Furthermore,
cause-specific mortality will be assessed through regular mortality follow-up.
Strengths of the present study are the large sample size, the generation of a considerable amount
of data, in particular outcome data, and the long-term aspect of the study. Furthermore, data on the
occurrence of the acute event are gathered through a face-to-face interview with the patients. Finally,
from the study participants, blood is collected and stored. However, the study also has limitations.
It is possible that selection bias will occur because patients who are more ill may refuse participation in
the study. The present study is designed as a single-center and not as a multicenter study. Finally,
another limitation is expected to be a loss to follow-up and the occurrence of missing data.
Altogether, the SCHANA study will add to the current knowledge on the long-term course of
stroke and its subtypes. Through this study, prognostic factors regarding different outcomes will be
examined. Due to the availability of blood specimens, novel biomarkers which may be associated with
the disease course can be identified. Therefore, the results of the study might help guide the various
disciplines involved in treating patients with stroke.
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